Amgen TAPs second ImmunoGen licence
This article was originally published in Scrip
Amgen has exclusively licensed ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target. This is the second such licence to be taken by Amgen – it obtained the exclusive right to use ImmunoGen’s TAP technology for another undisclosed cancer target earlier this year (scripnews.com, September 22nd, 2009).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.